Gomaa, Dalia A. https://orcid.org/0000-0002-0465-7777
El‑Haggar, Sahar M.
El-Shanshory, Mohamed R.
El-Razaky, Osama
El‑Afify, Dalia R.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Clinical Study to Evaluate the Possible Efficacy and Safety of l-Arginine in Children with Sickle Cell Disease and Increased Tricuspid Regurgitant Jet Velocity: a Randomized Controlled Trial
https://doi.org/10.1007/s40272-025-00701-w
Funding for this research was provided by:
Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank
Tanta University
Article History
Accepted: 21 May 2025
First Online: 17 June 2025
Declarations
:
: Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).
: Dalia A. Gomaa, Sahar M. El‑Haggar, Mohamed R. El-Shanshory, Osama El-Razaky, and Dalia R. El‑Afify declare that they have no potential conflicts of interest that might be relevant to the content of this manuscript.
: Data and materials are available upon request.
: The study followed the principles of the Declaration of Helsinki. The study protocol was accepted by the Research Ethics Committee of Tanta University in October 2021. Approval number: 34969 (10/21).
: Before participating in this study, written informed consent was obtained from all parents.
: Not applicable.
: Not applicable.
: All authors made major contributions to the trial design and manuscript. Patient enrollment was done by Dalia A. Gomaa and Mohamed R. El-Shanshory. Doppler echocardiography was performed by Osama El-Razaky. Laboratory analysis was performed by Dalia R. El‑Afify, and Dalia A. Gomaa. Statistical analysis was done by Sahar M. El‑Haggar and Dalia R. El‑Afify . The first draft of the manuscript was written by Dalia A. Gomaa. The final manuscript has been revised and approved by all authors